![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » DISCOVERY LABS SURFAXIN LICENSED IN ITALY BY DOMPE FARMACEUTICI
DISCOVERY LABS SURFAXIN LICENSED IN ITALY BY DOMPE FARMACEUTICI
October 24, 2005
Discovery Laboratories, Inc. (Nasdaq:DSCO) announced today that its development and marketing partner in Southern Europe, Laboratorios del Dr. Esteve, S.A. (Esteve) has sublicensed the distribution rights to Surfaxin(r) in Italy to Dompe Farmaceutici Spa (Dompe), a privately owned Italian company. Under this agreement Dompe will be responsible for sales, marketing and distribution in Italy of Surfaxin for the prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants.
PrimeZone (http://www.primezone.com/newsroom/news.html?ref=nrdigest&vid=1926&topic=4&d=88259)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct